Kidney Stones Research - Causes, Symptoms, Treatment, Diagnosis of Nephrolithiasis, Calculi

Kidney Stones Research Today is a free monthly online journal that collates and summarizes the latest research about Kidney Stones, including details on causes, symptoms, treatment, diagnosis of nephrolithiasis, calculi.


Kidney Stones Research Today

Home

View Latest Issue

Information About Kidney Stones

Books on Kidney Stones

Advertising in Research Today

View Other Research Today Publications



Biochemical and stone-risk profiles with topiramate treatment.

Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

BACKGROUND: Topiramate is a novel neuromodulatory agent commonly prescribed for the treatment of seizure disorders and for migraine headache prophylaxis. Calcium phosphate kidney stones have been observed with topiramate treatment, but a comprehensive elucidation of stone-risk profile was not reported previously. This study explores the relationship between topiramate treatment and propensity for kidney stone formation. METHODS: Thirty-two topiramate-treated subjects and 50 healthy volunteers participated in a cross-sectional study in which serum chemistry test and 24-hour urine collection results were evaluated for stone risk. Furthermore, a short-term longitudinal study was conducted in 7 patients to assess stone risk before and 3 months after topiramate treatment. RESULTS: Serum bicarbonate levels were lower with topiramate treatment. Urinary pH, urinary bicarbonate excretion, and fractional excretion of bicarbonate increased, whereas urinary citrate excretion was significantly lower (737 +/- 329 versus 278 +/- 226 mg/d; P < 0.001). Net acid excretion did not change. The relative saturation ratio for brushite increased with topiramate treatment (3.14 +/- 1.69 versus 1.27 +/- 1.26; P < 0.001) because of urinary alkalinization and decreased urinary citrate levels. Urinary saturation of undissociated uric acid decreased (41 +/- 52 versus 76 +/- 60 mg/d; P < 0.001). CONCLUSION: Treatment with topiramate causes systemic metabolic acidosis, markedly lower urinary citrate excretion, and increased urinary pH. These changes increase the propensity to form calcium phosphate stones.

Published 25 September 2006 in Am J Kidney Dis, 48(4): 555-63.
Full-text of this article is available online (may require subscription).

Place a permanent text-link or advertisement here for just US$15.

© 2004-2008 Kidney Stones Research Today. All Rights Reserved.



Kidney Stones Research Today Archive:

Volume 1 (2004)
  Issue 1 (September)
  Issue 2 (October)
  Issue 3 (November)
  Issue 4 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)



Kidney Stones Books

The Official Patient's Sourcebook on Kidney Stones: A Revised and Updated Directory for the Internet Age

The Official Patient's Sourcebook on Kidney Stones: A Revised and Updated Directory for the Internet Age